Tumors: a new treatment for lung cancer arrives

(ANSA) - ROME, 22 JAN - A new treatment for a particular form of lung cancer is also arriving in Italy. It is, in fact, Nsclc, the 'non-small cell' one in advanced stage and Alk positive (anaplastic lymphoma kinase) which has not previously been treated with Alk inhibitors. This is brigatinib alone. Brigatinib, manufactured by Takeda, is a next-generation tyrosine kinase inhibitor designed to selectively target and inhibit Alk genetic alterations. "In the treatment of non-small cell lung cancer, molecular profiling of the tumor is becoming increasingly important, which allows us to expand the therapeutic opportunities available for specific types of patients - declares Paolo Marchetti, full professor of oncology at the Sapienza University of Rome - In the case of patients with advanced non-small cell lung cancer, which presents rearrangement of the Alk gene, brigatinib represents an important available alternative, having shown in the pivotal clinical study significantly greater systemic efficacy than the comparator drug, with a manageable tolerability profile and a significant improvement in the quality of life of treated patients, measured with the Global Health Score index ". For Alessandra Bearz, Medical Director of Medical Oncology and Immunocorrelated Tumors at the Aviano Oncological Reference Center, "today we are in a position to have multiple drugs directed against Alk, with ever greater efficacy, in particular with greater ability to hit the target and to reach all tissues, including the brain, frequent site of secondary localizations in this pathology ", comments. (ANSA).